Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
1(50.0%)
N/A
1(50.0%)
2Total
Phase 2(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07298707Not Yet Recruiting

Cervical Cytology DNA Methylation for Endometrial Lesion Screening and Follow-up

Role: collaborator

NCT06390306Recruiting

The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP

Role: collaborator

NCT06531525Phase 2Not Yet Recruiting

Effect of Low Molecular Heparin on Pregnancy Outcome With Protein S Deficiency

Role: collaborator

NCT06297681Not Yet Recruiting

Combination of Daratumumab and BD Regimen and Dapagliflozin in the Treatment of M-protein Related Cardiac Disease

Role: collaborator

NCT02635048Not ApplicableCompleted

Mini-PCNL Versus Standard-PCNL For The Management of 20-40 mm Size Kidney Stones

Role: collaborator

All 5 trials loaded